Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer

Lesley Fallowfield, Rhona McGurk, Michael Dixon

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study was to determine the treatment preferences (adjuvant goserelin or cyclophosphamide, methotrexate and fluorouracil (CMF) chemotherapy) of healthy premenopausal women should they hypothetically develop oestrogen-receptor (ER) positive early breast cancer. Two hundred pre or peri-menopausal women read two scenarios describing goserelin or chemotherapy. Information included: How and where treatments were administered, side-effects, their likely persistence and impact on fertility. Women stated their unprompted initial and final preferences with reasons for the choices made. Respondents showed an overwhelming preference for goserelin. 156 (78%) women favoured goserelin, 22 (11%) chemotherapy and 22 (11%) remained undecided (P
Original languageEnglish
Pages (from-to)2403-10
Number of pages8
JournalEuropean journal of cancer (Oxford, England : 1990)
Volume40
Issue number16
DOIs
Publication statusPublished - Nov 2004

Keywords

  • Activities of Daily Living
  • Adult
  • Antineoplastic Agents, Hormonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Chemotherapy, Adjuvant
  • Cyclophosphamide
  • Female
  • Fertility
  • Fluorouracil
  • Goserelin
  • Humans
  • Interpersonal Relations
  • Methotrexate
  • Middle Aged
  • Patient Satisfaction
  • Premenopause
  • Time Factors

Fingerprint

Dive into the research topics of 'Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer'. Together they form a unique fingerprint.

Cite this